Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to $12.9 million.

  • Dianthus Therapeutics' Share-based Compensation rose 50.89% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.7 million, marking a year-over-year increase of 113.70%. This contributed to the annual value of $12.9 million for FY2024, which is 344.62% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Share-based Compensation of $12.9 million as of FY2024, which was up 344.62% from $2.9 million recorded in FY2023.
  • Dianthus Therapeutics' Share-based Compensation's 5-year high stood at $12.9 million during FY2024, with a 5-year trough of $1.5 million in FY2022.
  • Moreover, its 3-year median value for Share-based Compensation was $2.9 million (2023), whereas its average is $5.8 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Share-based Compensation plummeted by 85.27% in 2022, and later surged by 344.62% in 2024.
  • Over the past 5 years, Dianthus Therapeutics' Share-based Compensation (Yearly) stood at $9.9 million in 2020, then grew by 3.69% to $10.3 million in 2021, then slumped by 85.27% to $1.5 million in 2022, then surged by 91.04% to $2.9 million in 2023, then skyrocketed by 344.62% to $12.9 million in 2024.